

PDGFR-β
9Gly
IgG1 Fc
PDGFR(D1-D5)9G-Fc
sp D1 D2 D3 D4 D5 CH2 CH3
PDGFR(D1-D2)9G-Fc
sp D1 D2 CH2 CH3
PDGFR(D1-D3)9G-Fc
sp D1 D2 D3 CH2 CH3
PDGFR(D1-D4)
sp D1 D2 D3 D4
PDGFR(D1-D5)
sp D1 D2 D3 D4 D5

FIG. 1A



(D1-D4)
(D1-D5)
EGFP
(D1-D5)9G-Fc
(D1-D2)9G-Fc
(D1-D3)9G-Fc
(D1-D4)
(D1-D5)
EGFP
(D1-D5)9G-Fc
(D1-D2)9G-Fc
(D1-D3)9G-Fc
kDa
191
97
64
51
39
kDa
191
97
64
51
39
Reduced
Non-reduced

FIG. 1B



sPDGFR(D1-D5)9G-Fc
sPDGFR(D1-4)
sPDGFR(D1-D5)
PDGF BB [pM]
20
15
10
5
0
0.1
1
10
100
1000
Vol. Receptor CM

FIG. 2A



sPDGFR(D1-D5)-9G-Fc
sPDGFR(D1-D2)-9G-Fc
sPDGFR(D1-D3)-9G-Fc
PDGF BB [pM]
30
20
10
0
0.01
0.1
1
10
100
Receptor Vol (CM)

FIG. 2B



PDGFR(D1-D5)9G-Fc
PDGFR(D1-D3)9G-Fc
sFLT01
Flt/PDGFR Hybrid#1
PDGFR/Flt Hybrid#2
Flt/PDGFR Hybrid#3
PDGFR/Flt Hybrid#4
PDGFR-β
Flt-1
9Gly
9Ser
IgG1 Fc
sp
D1
D2
D3
D4
D5
CH2
CH3

FIG. 3



(D1-D5) 9G-Fc
Hyb#1
Hyb#2
Hyb#3
Hyb#3
Hyb#4
Hyb#4
Hyb#3
Hyb#3
Hyb#4
Hyb#4
kDa
Anti-PDGFRβ
191
97
64
51
Anti-Flt
191
97
64
51
39
28
Reduced
Non-reduced

FIG. 4



0.0
0.2
0.4
0.6
0.8
Control
VEGF+
(D1-D5)9G-Fc
Hyb#1
Hyb#2
Hyb#3
Hyb#4
sFLT01
***
VEGF+
PDGF BB+

FIG. 5B



O.D.490nm
0.0
0.2
0.4
0.6
0.8
Control
VEGF+
(D1-D5)9G-Fc
Hyb#1
Hyb#2
Hyb#3
Hyb#4
sFLT01
***
VEGF+

FIG. 5A



VEGF Binding
Hyb #1
Hyb #2
Hyb #3
Hyb #4
sFLT01
pM VEGF (dimer)
20
15
10
5
0
0.1
1
10
100
Volume Receptor (ul)

FIG. 6A



PDGF BB Binding
Hyb #1
Hyb #2
Hyb #3
Hyb #4
(D1-D5)9G-Fc
pM ligand (BB dimer)
100
80
60
40
20
0
0.1
1
10
100
1000
Volume Receptor (ul)

FIG. 6B



PDGF BB Competitive Binding Assay
pM PDGF BB (dimer)
25
20
15
10
5
0
0.01
0.1
1
10
100
Volume Receptor (ul) CM
Hyb #3
Hyb #4
(D1-D3)9G-Fc

FIG. 7A



VEGF Competitive Binding Assay
pM VEGF (dimer)
8
6
4
2
0
0.01
0.1
1
10
100
Volume Receptor (ul) CM
Hyb #3
Hyb #4
sFLT01

FIG. 7B



Percentage of Burns without Neovascularization
Burns without NV (%)
100
80
60
40
20
0
p < 0.0001
p < 0.0038
not sig.
Hybrid-4
Naive
sFLT02
Naive
PDGFR
Naive

Figure 8